The PI3K pathway is frequently mutated in cancer, but inhibitors of this pathway have largely disappointed in the clinic. A new study, published in Nature, shows a keto diet dramatically sensitizes tumors to PI3K inhibitors in pre-clinical models.

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →